Figure 3.

Suppression of SLC7A11 sensitizes anti-PD-L1 treatment caused by MerTK

(A) Volcano plot of differentially expressed proteins in protein mass spectrometry.

(B) Western blot of SLC7A11 expression in Hepa1-6, Res1-6, HCA-1, and Res-CA1.

(C) IHC staining of SLC7A11 in Hepa1-6, Res1-6, HCA-1, and Res-CA1 subcutaneous tumor tissues.

(D) IHC staining of SLC7A11 expression in HCC tissues from sensitive and resistant patients with anti-PD-1/PD-L1 therapy, and statistical analysis.

(E) The correlation between MerTK and SLC7A11 expression in tumor tissues from HCC patients received anti-PD-1/PD-L1 therapy, Pearson product-moment correlation coefficients and p values are shown.

(F and G) (F) Schematic illustrating the procedure of anti-PD-L1 or IgG treatment in Res1-6 and Res1-6-shSLC7A11 subcutaneous tumor model, and (G) the representative images of subcutaneous tumor in different groups.

(H) Statistical analysis of tumor growth curves.

(I and J) Western blot analysis of p-MerTK, MerTK, SLC7A11, and β-actin expression in Hepa1-6, Hepa1-6-OE-MerTK, Res1-6, and Res1-6-shMerTK subcutaneous tumor treated with anti-PD-L1 or IgG.

All results are shown as mean ± SEM (n = 5). One- or two-way ANOVA was used to analyze the data; ∗∗p < 0.01 and ∗∗∗p < 0.001.